| 1 | 31543315 | Impact of oral anticoagulation on proximal femur fractures treated within 24 h - A retrospective chart review. | Injury | 2019 Nov |
1 |
| 2 | 31545497 | Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins. | Mol Med Rep | 2019 Nov |
1 |
| 3 | 31591378 | ADP secreted by dying melanoma cells mediates chemotaxis and chemokine secretion of macrophages via the purinergic receptor P2Y12. | Cell Death Dis | 2019 Oct 7 |
1 |
| 4 | 31624788 | Platelet CD40 ligand and bleeding during P2Y12 inhibitor treatment in acute coronary syndrome. | Res Pract Thromb Haemost | 2019 Oct |
1 |
| 5 | 31811715 | Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. | Eur Heart J | 2020 May 1 |
1 |
| 6 | 31820856 | Ticagrelor Improves Remodeling, Reduces Apoptosis, Inflammation and Fibrosis and Increases the Number of Progenitor Stem Cells After Myocardial Infarction in a Rat Model of Ischemia Reperfusion. | Cell Physiol Biochem | 2019 |
5 |
| 7 | 31845894 | Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. | EuroIntervention | 2020 Apr 3 |
1 |
| 8 | 31849282 | Cost-effectiveness of <i>CYP2C19</i> LOF-guided antiplatelet therapy in Chinese patients with acute coronary syndrome. | Pharmacogenomics | 2020 Jan |
1 |
| 9 | 31850373 | Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing. | Front Cardiovasc Med | 2019 |
1 |
| 10 | 31860559 | Early versus delayed treatment with ticagrelor on residual thrombus after percutaneous coronary intervention in patients presenting with non-ST-elevation acute coronary syndrome: an optical coherence tomography study. | Coron Artery Dis | 2020 Mar |
1 |
| 11 | 31863577 | Beneficial Effects of Ticagrelor on Oxidized Low-Density Lipoprotein (ox-LDL)-Induced Apoptosis in Human Umbilical Vein Endothelial Cells. | Med Sci Monit | 2019 Dec 21 |
5 |
| 12 | 31968611 | Antiplatelet Drug Ticagrelor Enhances Chemotherapeutic Efficacy by Targeting the Novel P2Y12-AKT Pathway in Pancreatic Cancer Cells. | Cancers (Basel) | 2020 Jan 20 |
1 |
| 13 | 31997026 | Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD. | Curr Cardiol Rep | 2020 Jan 29 |
1 |
| 14 | 32027168 | Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review. | J Cardiovasc Pharmacol Ther | 2020 May |
1 |
| 15 | 32065000 | CYP2C19 and CYP3A4 activity and ADP-induced platelet reactivity in prasugrel- or ticagrelor-treated STEMI patients: monocentric study in PRAGUE-18 trial participants. | Xenobiotica | 2020 Aug |
2 |
| 16 | 32066489 | Ticagrelor and preconditioning in patients with stable coronary artery disease (TAPER-S): a randomized pilot clinical trial. | Trials | 2020 Feb 17 |
3 |